Alessia Bari

Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study

Stefano Sacchi, Luigi Marcheselli, Alessia Bari et al. · Haematologica · 2008 · 106 citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population‐based analysis

Samantha Pozzi, Luigi Marcheselli, Alessia Bari et al. · British Journal of Haematology · 2013 · 99 citations · Full text

Medicine, Oncology, Cancer Pharmacology +12

Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

Tamar Tadmor, Alessia Bari, Stefano Sacchi et al. · Haematologica · 2013 · 94 citations · Full text

Medicine, Hematology, Oncology +16

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Marco Ladetto, Chiara Lobetti‐Bodoni, Barbara Mantoan et al. · Blood · 2013 · 93 citations · Full text

Medicine, Hematology, Immunology +17

Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story

Alessia Bari, Luigi Marcheselli, Stefano Sacchi et al. · Annals of Oncology · 2009 · 89 citations · Full text

Medicine, Hematology, Oncology +16